The PI3K-specific inhibitors Alpelisib (BYL-719) and Inavolisib (GDC0077) inhibit the proliferation of multiple <i>PIK3CA</i>-mutated cervical cancer cell lines, but not a <i>PIK3CA</i> wild-type (WT) line. The gene discussed is PIK3CA; the disease is cervical carcinoma.